Dianthus Therapeutics

DNTH · NASDAQ

$78.75+$4.21 (+5.65%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $74.54

Latest news

Press releaseSep 29, 8:00 AM ETGlobe Newswire
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting
Press releaseSep 1, 8:00 AM ETGlobe Newswire
Dianthus Therapeutics to Participate in Three Investor Conferences During September
Press releaseAug 4, 4:01 PM ETGlobe Newswire
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results
Press releaseAug 4, 7:00 AM ETGlobe Newswire
Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases
Press releaseJun 29, 7:00 AM ETGlobe Newswire
Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis
NewsJun 12, 1:20 PM ETVandana Singh
Why Is Dianthus Therapeutics Stock Trading Higher On Friday?
NewsJun 11, 9:09 AM ETVandana Singh
Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says
Press releaseMay 26, 4:01 PM ETGlobe Newswire
Dianthus Therapeutics to Participate in Two Investor Conferences
Press releaseMay 19, 3:00 PM ETGlobe Newswire
Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases
Press releaseMay 5, 4:01 PM ETGlobe Newswire
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
Press releaseMar 12, 4:01 PM ETGlobe Newswire
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Press releaseMar 10, 10:54 PM ETGlobe Newswire
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering
Press releaseMar 9, 4:01 PM ETGlobe Newswire
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering
NewsMar 9, 9:22 AM ETVandana Singh
Dianthus Therapeutics Stock Rallies—Rare Disease Study Success Fuels Optimism
NewsMar 9, 8:05 AM ET
12 Health Care Stocks Moving In Monday's Pre-Market Session
NewsMar 9, 7:36 AM ET
Dianthus Therapeutics Earnings Review: Q4 Summary
Press releaseMar 9, 7:09 AM ETGlobe Newswire
Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results
NewsMar 4, 10:00 AM ETAvi Kapoor
Latham Group, Babcock & Wilcox, B&G Foods And Other Big Stocks Moving Higher On Wednesday
NewsMar 4, 9:01 AM ET
Breaking Down Dianthus Therapeutics: 5 Analysts Share Their Views
Press releaseFeb 24, 7:00 AM ETGlobe Newswire
Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference
NewsFeb 11, 4:01 PM ET
What 4 Analyst Ratings Have To Say About Dianthus Therapeutics
Press releaseFeb 5, 7:00 AM ETGlobe Newswire
Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Press releaseJan 5, 7:00 AM ETGlobe Newswire
Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference
Press releaseNov 24, 7:00 AM ETGlobe Newswire
Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference
NewsNov 23, 4:28 PM ETGianni di Poce
The Insider Report: Prepare for the Next Dip Buying Opportunity
Press releaseNov 5, 4:01 PM ETGlobe Newswire
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
Press releaseNov 4, 8:00 AM ETGlobe Newswire
Dianthus Therapeutics to Participate in Four Investor Conferences During November
NewsSep 9, 10:01 AM ET
Analyst Expectations For Dianthus Therapeutics's Future
NewsSep 8, 10:42 AM ETVandana Singh
Dianthus Scores Early Success, Analyst Boosts Confidence In Broader Drug Pipeline
Press releaseAug 7, 4:01 PM ETGlobe Newswire
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
Press releaseMay 29, 7:00 AM ETGlobe Newswire
Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference
NewsMay 13, 9:01 AM ET
Breaking Down Dianthus Therapeutics: 5 Analysts Share Their Views
Press releaseMay 12, 4:01 PM ETGlobe Newswire
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
Press releaseApr 29, 7:00 AM ETGlobe Newswire
Dianthus Therapeutics to Participate in Two Upcoming Investor Events
Press releaseMar 11, 4:01 PM ETGlobe Newswire
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results
Press releaseFeb 26, 7:00 AM ETGlobe Newswire
Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences
Press releaseJan 30, 7:00 AM ETGlobe Newswire
Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences
Press releaseJan 8, 7:00 AM ETGlobe Newswire
Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
NewsDec 20, 2:00 PM ET
Forecasting The Future: 5 Analyst Projections For Dianthus Therapeutics
NewsNov 11, 11:03 AM ET
Evaluating Dianthus Therapeutics: Insights From 5 Financial Analysts
NewsNov 8, 4:01 PM ET
A Glimpse Into The Expert Outlook On Dianthus Therapeutics Through 4 Analysts
Press releaseNov 4, 7:00 AM ETGlobe Newswire
Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences
NewsSep 26, 8:00 AM ET
Expert Ratings For Dianthus Therapeutics
Press releaseSep 4, 7:00 AM ETGlobe Newswire
Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September
NewsAug 12, 3:00 PM ET
Navigating 4 Analyst Ratings For Dianthus Therapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting

Dianthus Therapeutics to Participate in Three Investor Conferences During September

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results

Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases

Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis

Why Is Dianthus Therapeutics Stock Trading Higher On Friday?

Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says

Dianthus Therapeutics to Participate in Two Investor Conferences

Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results

Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering

Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering

Dianthus Therapeutics Stock Rallies—Rare Disease Study Success Fuels Optimism

12 Health Care Stocks Moving In Monday's Pre-Market Session

Dianthus Therapeutics Earnings Review: Q4 Summary

Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results

Latham Group, Babcock & Wilcox, B&G Foods And Other Big Stocks Moving Higher On Wednesday

Breaking Down Dianthus Therapeutics: 5 Analysts Share Their Views

Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference

What 4 Analyst Ratings Have To Say About Dianthus Therapeutics

Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference

The Insider Report: Prepare for the Next Dip Buying Opportunity

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results

Dianthus Therapeutics to Participate in Four Investor Conferences During November

Analyst Expectations For Dianthus Therapeutics's Future

Dianthus Scores Early Success, Analyst Boosts Confidence In Broader Drug Pipeline

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results

Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference

Breaking Down Dianthus Therapeutics: 5 Analysts Share Their Views

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results

Dianthus Therapeutics to Participate in Two Upcoming Investor Events

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results

Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences

Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences

Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Forecasting The Future: 5 Analyst Projections For Dianthus Therapeutics

Evaluating Dianthus Therapeutics: Insights From 5 Financial Analysts

A Glimpse Into The Expert Outlook On Dianthus Therapeutics Through 4 Analysts

Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences

Expert Ratings For Dianthus Therapeutics

Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September

Navigating 4 Analyst Ratings For Dianthus Therapeutics